LumiraDx News

Raymond James Maintains Outperform on LumiraDx, Lowers Price Target to $0.8

BenzingaAug 28, 2023 07:19 ET

LumiraDx Analyst Ratings

BenzingaAug 28, 2023 07:19 ET

BTIG Keeps Their Buy Rating on LumiraDx (LMDX)

TipRanksAug 27, 2023 11:45 ET

The Latest Analyst Ratings for LumiraDx

BenzingaMay 17, 2023 14:01 ET

Goldman Sachs Maintains Neutral on LumiraDx, Lowers Price Target to $0.75

BenzingaMay 17, 2023 09:18 ET

Analysts Offer Insights on Healthcare Companies: LumiraDx (LMDX) and Aerovate Therapeutics (AVTE)

TipRanksMay 16, 2023 20:50 ET

Raymond James Remains a Buy on LumiraDx (LMDX)

TipRanksApr 10, 2023 12:31 ET

Analyst Ratings for LumiraDx

BenzingaApr 10, 2023 11:05 ET

Raymond James Maintains Outperform on LumiraDx, Lowers Price Target to $1.5

BenzingaApr 10, 2023 04:42 ET

Raymond James Maintains Outperform on LumiraDx, Lowers Price Target to $1.5

BenzingaApr 7, 2023 04:34 ET

LumiraDx (LMDX) Gets a Buy From Raymond James

TipRanksMar 22, 2023 12:27 ET

Raymond James Adjusts LumiraDx Price Target to $2 From $3.50, Maintains Outperform Rating

MT NewswiresMar 22, 2023 08:27 ET

Raymond James Maintains Outperform on LumiraDx, Lowers Price Target to $2

BenzingaMar 22, 2023 04:42 ET

LumiraDx (LMDX) Gets a Buy From BTIG

TipRanksNov 13, 2022 23:10 ET

Raymond James Adjusts Price Target on LumiraDx to $3.50 From $4, Maintains Outperform Rating

MT NewswiresNov 11, 2022 10:47 ET

Raymond James Remains a Buy on LumiraDx (LMDX)

TipRanksNov 11, 2022 07:40 ET

LumiraDx Analyst Ratings

Benzinga Analyst RatingsNov 11, 2022 04:12 ET

Raymond James Maintains Outperform on LumiraDx, Lowers Price Target to $3.5

Benzinga Real-time NewsNov 11, 2022 04:11 ET

LumiraDx Is Maintained at Buy by BTIG

Dow JonesAug 19, 2022 10:27 ET

LumiraDx Price Target Cut to $4.00/Share From $7.00 by BTIG

Dow JonesAug 19, 2022 10:27 ET